Refine by MP, party, committee, province, or result type.

Results 1-7 of 7
Sorted by relevance | Sort by date: newest first / oldest first

Health committee  The work in the pharmaceuticals touches on global health issues. I've worked in pharma in sub-Saharan Africa, and I'm still involved with my former Pfizer colleagues in some malaria programs. The work with pharma doesn't mean that the global health perspective that I had in the i

November 30th, 2009Committee meeting

Dr. Bernard Prigent

Health committee  Indeed, but you mentioned prevention, and there are a lot of prevention activities that reside in pharma. I have contributed to the study of preventive measures in a whole range of settings, with a pharma perspective. The fact that you're looking at something from a pharma perspe

November 30th, 2009Committee meeting

Dr. Bernard Prigent

Health committee  I think one of the specific things that I will bring to CIHR is the experience that I've acquired working in various provinces, where that research for the right interface between public and private has been set in motion. If you look at Quebec, if you look at British Columbia,

November 30th, 2009Committee meeting

Dr. Bernard Prigent

Health committee  The nomination of someone representing any sector does not touch on the mandate of independence. The independence is there. I find it hard to believe that the presence of one person from one sector could derail the mandate of the governing council. Once again, I have been asked

November 30th, 2009Committee meeting

Dr. Bernard Prigent

Health committee  You are absolutely right. We are currently dealing with complex research and development issues, which are issues being faced by the scientific community, both private and public, and which require closer cooperation. In fact, this calls for an enhanced quality of research in pub

November 30th, 2009Committee meeting

Dr. Bernard Prigent

Health committee  As I said in my presentation, there is a very strong framework that's put in place to manage conflict of interest. But before we talk about the tools, I want to refer to the fact that you don't leave integrity and standards of integrity when you move from a sector to another. The

November 30th, 2009Committee meeting

Dr. Bernard Prigent

Health committee  Thank you, Madam Chair. I wish to thank you and your colleagues for providing me with the opportunity to outline my role and contribution as a member of the governing council of the Canadian Institutes of Health Research. Let me begin by sharing with you my experience and crede

November 30th, 2009Committee meeting

Dr. Bernard Prigent